[go: up one dir, main page]

MX2017015236A - Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation. - Google Patents

Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Info

Publication number
MX2017015236A
MX2017015236A MX2017015236A MX2017015236A MX2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A MX 2017015236 A MX2017015236 A MX 2017015236A
Authority
MX
Mexico
Prior art keywords
acetylcysteine
glycine
supplementation
benefits
glutathione levels
Prior art date
Application number
MX2017015236A
Other languages
English (en)
Other versions
MX389285B (es
Inventor
Kirnon Stephen
Freedland Eric
V Sekhar Rajagopal
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2017015236A publication Critical patent/MX2017015236A/es
Publication of MX389285B publication Critical patent/MX389285B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a composiciones y métodos que se relacionan con el uso de glicina y N-acetilcisteína en una variedad de afecciones médicas relacionadas con niveles reducidos de glicina, N-acetilcisteína, y/o glutatión.
MX2017015236A 2015-05-28 2016-05-25 Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión. MX389285B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562167433P 2015-05-28 2015-05-28
PCT/US2016/034078 WO2016191468A1 (en) 2015-05-28 2016-05-25 Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels

Publications (2)

Publication Number Publication Date
MX2017015236A true MX2017015236A (es) 2018-11-09
MX389285B MX389285B (es) 2025-03-20

Family

ID=57393662

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017015236A MX389285B (es) 2015-05-28 2016-05-25 Beneficios de la suplementación con n-acetilcisteína y glicina para mejorar los niveles de glutatión.
MX2021014012A MX2021014012A (es) 2015-05-28 2017-11-27 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014012A MX2021014012A (es) 2015-05-28 2017-11-27 Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.

Country Status (10)

Country Link
US (4) US10952982B2 (es)
EP (1) EP3302459A4 (es)
JP (4) JP7074663B6 (es)
CN (2) CN107847475A (es)
AU (1) AU2016268340B2 (es)
BR (1) BR112017025499A2 (es)
CA (1) CA2987597A1 (es)
MX (2) MX389285B (es)
TW (1) TWI769981B (es)
WO (1) WO2016191468A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016268340B2 (en) * 2015-05-28 2021-07-08 Baylor College Of Medicine Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels
US20210315792A1 (en) * 2016-10-18 2021-10-14 Somahlution, Llc Dermatological compositions for providing nutrients to skin and methods thereof
SE540582C2 (en) 2016-12-22 2018-10-02 Scandibio Therapeutics Ab Substances for treatment of fatty liver-related conditions
JP2021503878A (ja) * 2017-11-21 2021-02-15 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 筋肉の質及び／又は筋量のためのオレウロペイン又はクルクミンを使用する組成物及び方法
AU2019218232B2 (en) 2018-02-09 2024-12-19 Decibel Therapeutics, Inc. Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent
WO2019204381A1 (en) * 2018-04-19 2019-10-24 BIDNER, Daniel Veterinary thick gel composition of high palatability containing antioxidants to decrease sarcopenia, osteopenia and dna damage from oxidative stress in dogs, and procedure for its obtention
JP7515407B2 (ja) * 2018-06-21 2024-07-12 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ニコチンアミドアデニンジヌクレオチド（ｎａｄ＋）前駆体及び少なくとも１種のケトン又はケトン前駆体を使用する組成物及び方法
IT201800006566A1 (it) * 2018-06-21 2019-12-21 Composizione per prevenire e trattare disordini uditivi e vestibolari
CN112752575A (zh) 2018-09-27 2021-05-04 雀巢产品有限公司 组氨酸、甘氨酸和其它氨基酸用于预防胰岛素抗性和/或糖尿病的用途
CA3110296A1 (en) 2018-09-27 2020-04-02 Societe Des Produits Nestle S.A. Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor
EP3873236B1 (en) * 2018-11-02 2025-02-26 Société des Produits Nestlé S.A. Powders containing a buffer salt and an amino acid, reconstitution of such a powder into a nutritional product, and methods of using such a nutritional product
US10813947B1 (en) 2019-05-31 2020-10-27 Decibel Therapeutics, Inc. Methods of otoprotection against platinum-based antineoplastic agents
EP3756648A1 (en) * 2019-06-27 2020-12-30 Imnate Sarl Improved vaccine formulations
WO2020262114A1 (ja) * 2019-06-28 2020-12-30 有機合成薬品工業株式会社 ミトコンドリア機能活性化剤
CN110152004B (zh) * 2019-07-08 2021-09-03 天津医科大学 甘氨酸在制备药物递送增强剂及细胞移植试剂方面的用途
US11717554B2 (en) * 2019-09-19 2023-08-08 Max R&D Llc Method for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s)
JP2023502966A (ja) * 2019-11-18 2023-01-26 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 脳の健康に使用するためのグルタチオンの増強のための組成物及び方法
WO2021127541A1 (en) * 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
CA3166897A1 (en) * 2020-04-01 2021-10-07 Societe Des Produits Nestle S.A. Compositions and methods containing n-acetylcystein and nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230180811A1 (en) * 2020-04-29 2023-06-15 Societe Des Produits Nestle S.A. A nutritional product containing a buffer composition and an amino acid and methods of using such a nutritional product
US20210369661A1 (en) * 2020-05-27 2021-12-02 Immunoflex Therapeutics Inc. Methods and compositions for treating and recovering from viral infections
CN116546981A (zh) * 2020-12-18 2023-08-04 雀巢产品有限公司 使用至少一种甘氨酸或其衍生物和/或至少一种n-乙酰半胱氨酸或其衍生物以及至少一种百里酚和/或香芹酚的组合物和方法
WO2023158505A1 (en) * 2022-02-16 2023-08-24 Prothione Llc Compositions and methods for the treatment of human immunodeficiency virus
WO2024099883A1 (en) * 2022-11-07 2024-05-16 Société des Produits Nestlé S.A. Compositions and methods using glycine to reduce biological age of an adult animal
GB202311877D0 (en) * 2023-08-02 2023-09-13 Mars Inc Companion animal supplementation
US12458686B1 (en) 2025-04-02 2025-11-04 Goa Therapeutics Corporation Compositions and methods for reducing blood ethanol concentration through alcohol dehydrogenase and acetaldehyde scavengers

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792110A (en) * 1996-06-26 1998-08-11 Cunningham; Miles G. Systems and methods for delivering therapeutic agents to selected sites in a subject
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
WO1999043697A1 (en) * 1998-02-25 1999-09-02 The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
US7351427B2 (en) * 1998-06-18 2008-04-01 Busulipo Ab Pharmaceutical composition, a method of preparing it and a method of treatment by use thereof
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
JP2004526793A (ja) * 2001-04-25 2004-09-02 コバルツ リミテッド 個体における機能性ビタミンｂ１２欠乏症を治療または予防するための方法、およびこの方法に使用するための医療用組成物
AU2002339696A1 (en) * 2001-12-03 2003-06-17 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
US20040120983A1 (en) 2002-12-23 2004-06-24 Philip Connolly Nutritional supplement
CA2454749A1 (en) * 2002-12-31 2004-06-30 Glen A. Gordon Method and apparatus for pulsed electromagnetic therapy
US8697679B2 (en) * 2003-03-07 2014-04-15 N.V. Nutricia Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress
WO2005067972A1 (en) * 2003-12-31 2005-07-28 Integrative Health Consulting, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
US20060116334A1 (en) * 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
US20060160721A1 (en) * 2004-12-22 2006-07-20 Baylor College Of Medicine Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
US7754700B2 (en) * 2006-04-24 2010-07-13 Trager Seymour F Composition and methods for alleviating symptoms of neurotoxicity
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
US20110052556A1 (en) * 2008-02-29 2011-03-03 Biolab Sanus Farmaceutical Ltda Pharmaceutical composition comprising racetam and carnitine and process for its preparation
EP2189453A1 (en) * 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
US8362080B2 (en) * 2008-12-18 2013-01-29 Baylor College Of Medicine Increasing glutathione levels for therapy
AU2009217433A1 (en) * 2009-03-05 2010-09-23 Newcastle Innovation Limited Diagnostic, prognostic and treatment methods
US20110104137A1 (en) * 2009-04-21 2011-05-05 Chronorx Llc, An Alaska Limited Liability Company ADJUNCTS AND COMPLEXES FOR IMPROVING HMG-CoA REDUCTASE INHIBITOR (STATIN) AND SELECTIVE PHOSPHODIESTERASE 5 INHIBITOR THERAPY
US8796315B2 (en) * 2009-06-25 2014-08-05 Darlene E. McCord Methods for improved wound closure employing olivamine and human umbilical vein endothelial cells
US8916606B2 (en) * 2009-10-27 2014-12-23 William Marsh Rice University Therapeutic compositions and methods for targeted delivery of active agents
WO2013063615A2 (en) * 2011-10-28 2013-05-02 Yu Ruey J N-acyldipeptide derivatives and their uses
WO2013072714A1 (en) * 2011-11-15 2013-05-23 Centre National De La Recherche Scientifique (Cnrs) Antibodies for molecular imaging of vulnerable plaques in atherosclerosis
BR112014019480A8 (pt) * 2012-02-07 2017-07-11 Xenoport Inc Composto fumarato de morfolinoalquila,composição farmacêutica,e,uso dos mesmos
US8747894B2 (en) * 2012-05-08 2014-06-10 Alpex Pharma S.A. Effervescent compositions containing N-acetylcysteine
US20140006042A1 (en) * 2012-05-08 2014-01-02 Richard Keefe Methods for conducting studies
EP2869717B8 (en) * 2012-07-09 2018-07-25 NoGlo, Inc. Prevention of alcohol reaction with dietary supplements
US9144555B2 (en) * 2012-11-30 2015-09-29 Darlene E. McCord Hydroxytyrosol and oleuropein compositions for induction of DNA damage, cell death and LSD1 inhibition
CN106455705A (zh) * 2014-01-22 2017-02-22 方特慕控股第私人有限公司 用于吸烟欲望救济的方法和装置
CN106458839A (zh) * 2014-04-08 2017-02-22 纽维制药有限公司 用于增加atp生产的琥珀酸的前药
EP3166602A4 (en) * 2014-07-09 2018-03-07 McCord, Darlene E. Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition
WO2016033183A1 (en) * 2014-08-29 2016-03-03 Crum Albert B A method for side effect reduction in the use of statins via physiologically synthesized glutathione
US20160302451A1 (en) * 2015-04-16 2016-10-20 Michael Hudnall Medical Food for Patients with Chronic Liver Disease
AU2016268340B2 (en) * 2015-05-28 2021-07-08 Baylor College Of Medicine Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels

Also Published As

Publication number Publication date
JP2018516280A (ja) 2018-06-21
EP3302459A4 (en) 2019-02-20
CA2987597A1 (en) 2016-12-01
US10952982B2 (en) 2021-03-23
EP3302459A1 (en) 2018-04-11
JP2025003996A (ja) 2025-01-14
JP2023022033A (ja) 2023-02-14
JP7074663B6 (ja) 2022-08-01
JP2021073181A (ja) 2021-05-13
BR112017025499A2 (pt) 2018-08-07
US11730711B2 (en) 2023-08-22
US12186292B2 (en) 2025-01-07
US20180161297A1 (en) 2018-06-14
MX389285B (es) 2025-03-20
US20230137543A1 (en) 2023-05-04
TW201707696A (zh) 2017-03-01
TWI769981B (zh) 2022-07-11
MX2021014012A (es) 2022-01-06
US20240041812A1 (en) 2024-02-08
JP7074663B2 (ja) 2022-05-24
AU2016268340A1 (en) 2017-11-30
WO2016191468A1 (en) 2016-12-01
CN115957294A (zh) 2023-04-14
AU2016268340B2 (en) 2021-07-08
JP7629432B2 (ja) 2025-02-13
US20210244696A1 (en) 2021-08-12
CN107847475A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
MX2017015236A (es) Beneficios de la suplementacion con n-acetilcisteina y glicina para mejorar los niveles de glutation.
CL2017002161A1 (es) Jarabes de alulosa
BR112016024494A8 (pt) análogo de peptídeo e seu uso
MX2019011496A (es) Composiciones de niraparib.
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
EA201790722A1 (ru) КОМПОЗИЦИЯ С НИЗКИМ pH, СОДЕРЖАЩАЯ КОНКРЕТНЫЕ КОНСЕРВАЦИОННЫЕ СИСТЕМЫ
BR112018007356A2 (pt) métodos de produção de formas fucosiladas e não fucosiladas de uma proteína
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR112016006048A8 (pt) composições antimicrobianas
MX2017008277A (es) Solucion oftalmica acuosa.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
AU357379S (en) Low profile pump
MX2016008719A (es) Fertilizador de urea con dureza mejorada.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
MX2018007871A (es) Composiciones para el cuidado personal.
UY36107A (es) Composición microencapsulada inhibidora de la nitrificación
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX2018000634A (es) Nueva especie de tobamovirus.
DOP2017000260A (es) Piroglutamato de vortioxetina
MX2020004748A (es) Composiciones y metodos para mejorar el uso de fosforo y calcio de la dieta en animales.
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
MX2019013251A (es) Una composicion nutricional para usarse para mejorar la atencion y/o reducir la impulsividad.
BR112018005849A2 (pt) fundos bioativos